Introduction
Ceruloplasmin is an abundant plasma protein that carries -95% of the total circulating copper. It is a monomer of 132 kD composed almost entirely of three 42-45-kD domains that are highly homologous to each other (1) and to the three do-A portion of this work has appeared in abstract form ( 1993. Circula- mains that make up the large, active proteolytic subunits of factors V and VIII of the coagulation cascade (2). Ceruloplasmin is an acute phase protein with a response of intermediate magnitude compared with other acute phase proteins; the plasma concentration is increased two-to threefold during inflammation, pregnancy, and after traumatic injury, including surgery (see references 3 and 4 for review).
The physiological function of ceruloplasmin has been a subject of considerable investigation, speculation, and contradiction. Multiple biochemical activities of ceruloplasmin have been described, including copper transport, oxidation of various amines, oxidation of Fe2+ to Fe3+ for subsequent uptake by transferrin and ferritin, and antioxidant activity against lipid peroxidation (see references 4 and 5 for evidence for and against these functions). Reported cellular actions of ceruloplasmin include stimulation ofcell proliferation (6) and angiogenesis (7) . Ceruloplasmin's antioxidant property has been consistently observed by many laboratories (8) (9) (10) (11) (12) (13) , and is thought by some to be responsible for a large portion of the antioxidant capacity of serum (8) . The antioxidant action has been proposed as a crucial function of ceruloplasmin during inflammatory and acute phase responses ( 14) . Multiple mechanisms have been proposed to explain ceruloplasmin antioxidant activity, including scavenging of superoxide and other reactive oxygen species (10) , and inhibiting the Fenton reaction by conversion of Fe2+ to Fe3+ (ceruloplasmin is also called "ferroxidase") ( 12, 15) . The latter mechanism is supported by a considerable body of evidence, but the ability of ceruloplasmin to block Cu2 -mediated lipid oxidation suggests that alternate antioxidant mechanisms must also pertain ( 16) . There is evidence that ceruloplasmin as an antioxidant blocks protein ( 17) and DNA damage ( 18) , and that it affords protection against free radical-initiated cell injury and lysis ( 19) .
Ceruloplasmin has been shown to inhibit the oxidation of tissue homogenates (8) , tissue extracts of lipids (18) , microsomal membranes ( 1 1, 12, 20) , and vesicles ofpurified polyunsaturated fatty acids (9) and phospholipids (10) , but its role in the oxidation of plasma lipoproteins has received little attention. This activity of physiological antioxidants has become a subject of intense interest since there is convincing evidence that lipoproteins are modified by oxidation in vivo. Lipoprotein particles resembling oxidized forms have been observed in normal human plasma (21, 22) , in plasma of diabetic subjects (23) , and in the serum of patients with cardiovascular diseases (24) . The data demonstrating the presence of oxidized LDL within arterial lesions are particularly strong (25) . Evidence that lipid oxidation has a causative role in lesion formation is largely circumstantial and based on in vitro studies. However, recent data show that several antioxidants reduce atherosclerosis progression in various animal models (26) (27) (28) (29) , and some activity, possibly via cell-mediated free radical processes, or deficiencies in the antioxidant activity of host defense systems. We therefore examined the ability of ceruloplasmin, as a putative plasma antioxidant, to protect LDL against modification by copper ion-mediated free radical oxidation. Our results indicate that ceruloplasmin can exhibit a potent oxidant, rather than antioxidant, activity that depends on specific structural properties of the molecule.
Methods
Materials. LDL and ceruloplasmin were isolated from fresh human plasma (< 48 h) obtained from the American Red Cross. Rabbit polyclonal antibodies against human ceruloplasmin and human a1-antitrypsin were obtained from Accurate Chemical Co. (Westbury, NY). Chromatographic media were purchased from Pharmacia LKB Biotechnology AB (Uppsala, Sweden), and Chelex-l00 was from Bio-Rad Laboratories (Richmond, CA). Other reagents were from Sigma Chemical Co. (St. Louis, MO) unless otherwise noted.
Preparation ofhuman ceruloplasmin. Ceruloplasmin was purified from human plasma by a modification (3 la) ofthe method ofNoyer et al. (32) . In brief, QAE-Sephadex A50 batch chromatography, ammonium sulfate precipitation, hydroxyapatite chromatography, Sephadex G50 chromatography, ultrafiltration, and Mono Q fast protein liquid chromatography steps were applied sequentially. Hydroxyapatite chromatography yielded two peaks of ceruloplasmin differing only in carbohydrate content (33) . The major fraction, referred to as ceruloplasmin I (or for brevity, just ceruloplasmin), has three N-linked oligosaccharides, while the lesser fraction, ceruloplasmin II, has only two oligosaccharides (4) . Each of these fractions was separately subjected to the subsequent purification steps. The procedure was monitored by ceruloplasmin oxidase activity measured essentially as described by Sunderman and Nomoto (34) with p-phenylenediamine as substrate.
The term "oxidase activity" is used here to refer to the ability ofceruloplasmin to oxidize p-phenylenediamine, while "oxidant activity" refers to the oxidation of LDL by ceruloplasmin (see below). Ceruloplasmin protein was determined by absorbance (OD'm,6i0nm = 0.66) and total protein with bicinchoninic acid (Bio-Rad Laboratories) using bovine serum albumin as standard. The purification procedure yielded ceruloplasmin preparations that were essentially pure as determined by ceruloplasmin oxidase specific activity (34) , by an absorbance ratio (610/280 nm) > 0.045 (4, 35) , and by homogeneity according to SDS-PAGE and silver staining. Purified ceruloplasmin was primarily the intact 132-kD monomer, but also contained a small amount (< 10% by silver stain of SDS-PAGE) of the 115-and 19-kD proteolytic fragments of ceruloplasmin also present in serum (36) . The 1 15-kD fragment has been observed in most preparations ofceruloplasmin (unless it is further degraded to 50-and 67-kD fragments) (37, 38) . Ceruloplasmin prepared by this procedure was completely stable for prolonged periods (> 1 mo at 370C) due to the removal ofan endogenous metalloproteinase that specifically cleaved intact, 1 32-kD ceruloplasmin into 1 Lipoprotein methods. Human LDL was prepared from freshly drawn, citrated normolipemic plasma to which EDTA was added before ultracentrifugation. LDL (density = 1.019-1.063 g/ml) was isolated by sequential ultracentrifugation as described previously (40) .
Immediately before use, LDL was extensively dialyzed at 4VC against saline. LDL (1 mg/ml cholesterol, final concentration) was oxidized by incubation with CuS04 (0.7-1.0 MM) and other test materials in 0.05 ml PBS for 20-24 hat 37"C. Lipoprotein oxidation was measured as formation of thiobarbituric acid-reacting substances (TBARS)' by a modification (41 ) of the method of Schuh et al. (42) . Duplicate lipoprotein samples were compared with a standard curve prepared with malondialdehyde (MDA), and TBARS, detected by fluorescence at 515 nm excitation/ 553 nm emission, were expressed as nanomoles of MDA equivalents per milligram LDL cholesterol. In some experiments lipoprotein oxidation was continuously monitored as the formation of conjugated dienes by absorbance at 234 nm (43) . The total lipid peroxide content of modified lipoproteins was measured as described by El-Saadani et al. (44) . Relative electrophoretic mobility of modified LDL was determined by electrophoresis on 1% agarose gels (Ciba Corning, Palo Alto, CA) as described by Morel et al. (40) , except that the electrophoresis was extended to 45 min to improve separation.
Results
Oxidant activity ofceruloplasmin. To investigate the hypothesis that human ceruloplasmin protects lipoproteins against oxidative modification, we examined its effect on copper ion-induced oxidation of human plasma LDL. CUSO4 alone increased LDL TBARS by -15-fold to 16 nmol MDA equivalents/mg cholesterol, a stimulation consistent with previous reports (45, 46) . Surprisingly, the addition of purified, intact human ceruloplasmin did not suppress the oxidation of LDL by CuS04, but rather augmented it in a dose-dependent manner to as much as 25 nmol MDA/mg cholesterol (Fig. 1) . To test if the oxidant activity of ceruloplasmin required exogenous copper ions, the effect of ceruloplasmin by itself was tested. Incubation of LDL with ceruloplasmin for 24 h increased oxidation levels by -40-fold to 39 nmol MDA/mg cholesterol at the normal (nonevoked) physiological plasma concentration of 300 ug/ml (Fig. 2) . Potent oxidant activity was observed in all 4 preparations of ceruloplasmin (isolated from different pools of plasma) that were tested, and using at least 10 separate preparations of LDL. Ceruloplasmin oxidant activity was comparable to that of CuS04 (when expressed as moles of ceruloplasmin protein and moles of CuS04), with the activity of different ceruloplasmin preparations ranging from about half as potent to twice as potent as the soluble salt (not shown). Ifceruloplasmin copper is involved in oxidant activity (see below), then it is likely that not all copper atoms participate in the reaction or that the involved atoms are less effective than free copper. As a control to show whether ceruloplasmin altered the measurement of TBARS, ceruloplasmin was added to LDL immediately before the assay and was found to have no influence on the TBARS measured.
To verify that LDL was indeed oxidized by ceruloplasmin, other physical and chemical parameters of lipid and lipoprotein oxidation were measured. Since ceruloplasmin contains between six and seven atoms of copper per molecule (35, 47) , we speculated that the chemical characteristics of LDL oxidized by ceruloplasmin would be similar to those ofcopper-oxidized LDL. Concentrations of ceruloplasmin (100 gg/ml, 1 . Abbreviations used in this paper: MDA, malondialdehyde; TBARS, thiobarbituric acid-reacting substances. resis on agarose gels, followed by elution of the ceruloplasmin band. Fig. 4 cate that it is ceruloplasmin rather than a minor contaminant that is responsible for oxidant activity.
Regulation ofceruloplasmin oxidant activity. Since the oxidant action of ceruloplasmin was not consistent with previous reports of antioxidant activity, we tested the effect of ceruloplasmin from commercial suppliers used in most previous reports on oxidation of lipids. Commercial ceruloplasmin had essentially no capacity to oxidize LDL in the absence ofexogenous copper ion; the maximum oxidation level was 1-3 nmol MDA equivalents/mg cholesterol, compared with 20-40 for intact, purified ceruloplasmin (Fig. 6 ). When added in the presence ofCuSO4, commercial ceruloplasmin was found to be an antioxidant, a finding consistent with previous reports. This result contrasted with that for intact, 132-kD ceruloplasmin, which augmented copper ion-mediated LDL oxidation (Fig.  1) . According to SDS-PAGE, purified ceruloplasmin I was highly homogeneous and present primarily as an intact 1 32-kD protein with only a small amount(< 10%) ofthe 1 5-kDdegradation product. This proportion of intact protein to the 115-kD fragment is similar to that observed by Western blot analysis ofwhole plasma (36, and data not shown). Electrophoresis on a nondenaturing gel confirmed the purity of ceruloplasmin I (Fig. 6, inset) ; the 115-and l9-kD degradation products remained complexed under these conditions and cochromatographed with the intact protein. The 1 32-kD protein was entirely missing from the commercial preparation and was re- placed by lower molecular mass fragments (Fig. 6, inset) and, possibly, nonceruloplasmin contaminants. Similar antioxidant capacities were found using ceruloplasmin from several commercial sources, all ofwhich were highly degraded but retained normal levels of ceruloplasmin oxidase-specific activity that were comparable to that of purified ceruloplasmin I (not shown). To begin to understand the molecular mechanisms involved, we examined the role of ceruloplasmin structure in oxidant activity. We first examined whether the difference in structural integrity ofthe ceruloplasmin preparations could account for the observed difference in oxidant activity. Proteolytically modified ceruloplasmin was prepared by incubating highly purified, intact ceruloplasmin I with the plasma metalloproteinase that was isolated during the ceruloplasmin preparation and partially purified (3 la) . After incubation for 72 h at 370C, the 132-kD ceruloplasmin molecule was completely converted to the 115-kD fragment (Fig. 7 A, inset) . Both degraded and undegraded forms ofceruloplasmin were incubated with LDL for 24 h and the level of oxidation measured as TBARS. Proteolytically modified ceruloplasmin lost about three-fourths ofthe oxidant activity ofthe intact molecule ( (Fig. 7 B) . The antioxidant activity ofproteolytically modified ceruloplasmin was similar to that of bovine serum albumin and only moderately less than commercial ceruloplasmin. These findings are consistent with those of Gutteridge ( 16) , who has shown that, in a cupric ion system, the antioxidant activity of (degraded) ceruloplasmin is not unique, but rather is a nonspecific property of most proteins. Kalant and McCormick (48) have similarly shown that albumin and other serum proteins suppress metal ion-mediated oxidation of LDL. We compared the ability ofvarious proteins to inhibit ceruloplasmin-mediated as well as CuSO4-mediated LDL oxidation. All proteins and peptides tested suppressed both CuSO4-dependent (Fig. 8 A) and ceruloplasmin-dependent (Fig. 8 B) oxidation in a concentration-dependent fashion, and with a rank order of potency of lactalbumin hydrolysate > albumin proteolytically modified ceruloplasmin > gelatin > type I collagen. All proteins inhibited LDL oxidation by CuSO4 and by ceruloplasmin with similar potencies, suggesting that the mechanisms of oxidant activity by both agents may be related. The results show that protein contaminants can interfere with ceruloplasmin oxidant activity and, in conjunction with degradation, may account for differences in oxidant activity of ceruloplasmin preparations. They also show that in cupric ion-mediated or in intact ceruloplasmin-mediated oxidation, the antioxidant activity of degraded or commercial sources of ceruloplasmin is a nonspecific effect in common with many proteins.
Boundceruloplasmin copper is responsiblefor oxidant activity. The parallel time courses of oxidation of LDL by ceruloplasmin and by CuSO4 described above (and parallel inhibition by proteins) suggest that copper may be responsible for ceruloplasmin oxidant activity. Since the purification of ceruloplasmin involved multiple column elutions (some under conditions ofhigh ionic strength) and multiple filtration steps, we did not believe it likely that significant amounts of free copper could be copurifying with the protein. To test the possibility directly, the oxidant activity ofceruloplasmin was examined after thorough washing by ultrafiltration using I0-kD Microcon filters (Amicon Corp., Danvers, MA). Approximately 90% ofthe oxidant activity was retained by the filter and < 10% passed through, confirming the association ofthe oxidant copper atoms with ceruloplasmin. To further test the hypothesis that ceruloplasmin copper was responsible for LDL oxidation, we examined the ability of a chelating agent, Chelex-l00, to inactivate ceruloplasmin. Ceruloplasmin was incubated with Chelex-100 beads for 4 h at room temperature and the supernatant assayed for its ability to oxidize LDL. This treatment decreased ceruloplasmin copper content from -6.6 to 5.5 atoms per molecule of protein, a result consistent with the removal of 1 of 7 copper atoms as reported previously (47) . Incubation of ceruloplasmin with Chelex-100 completely suppressed the oxidant activity ofthe protein (Fig. 9 ) without significantly altering oxidase activity (not shown). As was the case with protease treatment, suppression ofceruloplasmin oxidant activity by treatment with Chelex-100 was accompanied by the appearance of antioxidant activity as determined by inhibition of LDL oxidation in the presence of CuSO,4 (not shown). Restoration ofcopper by incubation with CuSO4 (followed by ultrafiltration) almost completely restored oxidant activity to Chelex-treated ceruloplasmin. This demonstrates that the inactivation by Chelex-100 was not due to irreversible changes in the oxidant capacity ofthe protein and confirms the critical role of copper in ceruloplasmin oxidant activity.
Discussion
These experiments demonstrate that purified, undegraded human ceruloplasmin has potent oxidant activity towards LDL. We have several lines of evidence that this activity is due to ceruloplasmin itself and not to a minor contaminant: (a) the ceruloplasmin used in these experiments is homogeneous by silver staining of SDS-PAGE, by ceruloplasmin oxidase specific activity, and by an absorbance ratio (610/280 nm) of at least 0.045; (b) both glycosylated isoforms of ceruloplasmin have equal oxidant capability; (c) ceruloplasmin eluted from nondenaturing agarose gels is highly active; (d) two treatments known to specifically alter ceruloplasmin structure, i.e., incubation with a ceruloplasmin-degrading protease and with Che- Cerulopesmin (or equivalnt) (pgml) Figure 9 . Effect of copper depletion on ceruloplasmin oxidant activ- lex-100, also moderate oxidant activity; and (e) immunoprecipitation by a ceruloplasmin-specific antibody removed essentially all oxidant activity. The oxidant activity was unanticipated in view of reports from many laboratories that ceruloplasmin is a potent lipid antioxidant (see references 14 and 49 for review). We believe that the most likely source of the different results is the purity and structural integrity of ceruloplasmin itself. The purified ceruloplasmin used in this study is prepared from fresh plasma according to a modified protocol that removes a contaminating metalloproteinase and yields an intact 1 32-kD monomer with minimal degradation to the 11 5-kD or smaller fragments (3 1a). The ceruloplasmin from commercial sources is highly degraded with the 132-kD monomer entirely missing and replaced by smaller fragments. We have shown that specific degradation of ceruloplasmin to the 115-and l9-kD fragments is accompanied by the disappearance of oxidant activity and appearance of antioxidant activity. Similarly, highly degraded commercial ceruloplasmin lacks oxidant activity and is an apparent antioxidant in cupric ion-mediated oxidation of LDL.
While our results suggest a new physiological role for ceruloplasmin that is counter to most current ideas, the seemingly disparate findings are not incompatible. The antioxidant activity of ceruloplasmin can be ascribed to two of its properties. The first is a nonspecific, antioxidant effect that can be observed for almost any protein in, for example, a cupric ion-mediated lipid peroxidation reaction ( Fig. 7 and reference 16) . Second, the oxidase activity of ceruloplasmin, inherent in the intact, purified protein as well as in the degraded protein that dominates commercial preparations, participates in the redox cycling of iron. In lipid peroxidation processes that are iron rather than copper mediated, ceruloplasmin oxidizes ferrous ion to ferric ion and, according to the "mixed valence iron model" (50) , drives the iron equilibrium from an actively oxidizing mix of both valence states to the inactive ferric state, thus accounting for its antioxidant activity. These two properties could explain the previous reports showing ceruloplasmin to be an antioxidant.
Our results clearly implicate bound copper in ceruloplasmin oxidant activity. The first evidence is the resemblance of ceruloplasmin-oxidized LDL and copper-oxidized LDL with respect to multiple chemical and physical indicators of oxidation. When a concentration ofcopper is chosen so that the rate of formation of LDL TBARS matches that caused by a given concentration ofceruloplasmin, other measures ofLDL oxidation that we have tested also match closely. Furthermore, several proteins block the oxidation ofLDL mediated by both free copper and ceruloplasmin, suggesting similar mechanisms. Most importantly, treatment of ceruloplasmin with Chelex-100, which removes a single copper from ceruloplasmin, almost completely suppresses the oxidant activity, which can be subsequently restored by readdition of copper. However, just the presence ofthe oxidant copper atom(s) is not sufficient for oxidant activity since protease treatment completely suppresses the activity without removing any copper. This result is consistent with a structural modification of the molecule that blocks the accessibility ofthe oxidant copper site. Interestingly, neither chelation nor proteolysis alter ceruloplasmin oxidase activity, indicating that the active sites and specific copper atoms required for oxidase and oxidant activities may not be the same.
Little is known about the structure of ceruloplasmin in vivo. We and others (36) have shown by Western blot analysis that ceruloplasmin in plasma consists primarily of the intact 132-kD monomer accompanied by a small amount ofthe 1 5-kD degradation fragment. We therefore argue that circulating ceruloplasmin is predominantly in the form in which the oxidant rather than antioxidant activity may be expressed. Recent electron paramagnetic resonance studies ofplasma have shown that the spectrum of ceruloplasmin in plasma is essentially identical to purified ceruloplasmin (51) . In addition to the ceruloplasmin isoforms used in these experiments, other isoforms have been observed in plasma, including an apoceruloplasmin that is completely devoid ofcopper and a 200-kD molecule, but the amounts and roles ofthese proteins are uncertain (36, 52, 53) .
The mechanisms causing LDL oxidation in vivo are not known and we can only speculate on the role ofceruloplasmin in this process. There is some evidence for oxidized LDL in plasma (21, 54) . A process by which ceruloplasmin may oxidize circulating LDL that is then taken up by the artery wall may be envisioned. The accumulation of oxidatively modified LDL in the plasma may be limited by plasma antioxidants and by rapid removal by the liver (55). In an alternate scenario, ceruloplasmin may oxidize LDL within the arterial wall itself. There is as yet no evidence for ceruloplasmin in either normal or lesioned blood vessels. However, ceruloplasmin could accumulate in the vessel wall by at least two pathways: uptake and synthesis. In support ofthe first mechanism, specific high affinity receptors for ceruloplasmin have been described in liver endothelium (56) and in aortic extracts (57) . Alternatively, conditions or procedures that cause vascular injury (surgery or angioplasty), in which ceruloplasmin levels are elevated (58) and endothelial permeability to plasma-borne substances is increased, may result in high interstitial concentrations of both ceruloplasmin and lipoproteins. With respect to the second mechanism, while the liver is believed to be the primary site of synthesis of ceruloplasmin in the adult, activation of alveolar macrophages by inflammatory agents stimulates ceruloplasmin gene expression and protein production (59) . A similar activation and response by macrophages in vascular lesions is possible.
Vascular endothelial cells and smooth muscle cells oxidize LDL by mechanisms requiring transition metals (40, 60) , and activated human monocytes oxidize LDL even in metal ionpoor media (61, 62) . The role of ceruloplasmin in these processes has not been investigated. Much of the research on the mechanisms of oxidation of LDL by cells has been done with soluble metal ion-dependent systems; however, the existence of free iron and copper ions in vivo is uncertain. Our results invite speculation that the participation of copper in ceruloplasmin-bound form could be an in vivo analogue of metal ion-dependent oxidation of LDL, which could pertain in either cell-free and cell-dependent systems. Other transition metal-containing proteins may also participate in lipoprotein oxidation and, in fact, Balla et al. (63) have shown that the iron-binding protein hemin can oxidize LDL in vitro. Their observations differ from our own in that hemin-mediated oxidation requires a source ofperoxides and the addition ofexogenous metal ion.
The physiological role of ceruloplasmin has not yet been identified with certainty. Menkes' and Wilson's diseases are inherited human disorders characterized by markedly reduced plasma ceruloplasmin levels (64) . These diseases, however, are not particularly informative about the physiological or pathological functions of ceruloplasmin, since the primary defect does not reside within the ceruloplasmin gene, but rather involves defective cellular copper transport, which is likely to affect all copper proteins (65) . Our findings recommend a cautious approach when considering the physiological role of ceruloplasmin. Although much previous evidence supports its role as an antioxidant that protects lipids and cells against free radical-induced injury, ceruloplasmin may also have a damaging, oxidant activity. The structure ofthe molecule in vivo may be of paramount importance in determining its action. Our data indicate that the proportion ofceruloplasmin in the undegraded 132-kD form (compared with degraded) and the presence or chemical coordination of complexed copper atoms are critical parameters in determining the net oxidant activity. The importance ofoxidant activity in the physiological role ofceruloplasmin is not known, but it may be central in its primary function, e.g., as a participant in the host defense system through an injurious oxidant action on invasive organisms. This activity is consistent with ceruloplasmin's role in the acute phase response occurring after infection or inflammation and, in fact, a bactericidal activity has been recently reported (66) . Inactivation ofceruloplasmin by a metalloproteinase may represent a physiological mechanism to limit the scope ofits acute oxidant action. The ability of ceruloplasmin to oxidatively modify LDL may help to explain recent studies showing that serum ceruloplasmin is an independent risk factor in the prediction of myocardial infarction and cardiovascular disease (67-70).
